These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35145913)

  • 1. First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations.
    Hu X; Li H; Kang X; Wang X; Pang H; Liu C; Zhang J; Wang Y
    Front Oncol; 2022; 12():766066. PubMed ID: 35145913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
    Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
    Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
    Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
    Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic
    Zhao X; Zhang S; Sun X; Lin Y; Capone L; Ko EC; Kann BH; Li Y; Wang X
    Transl Lung Cancer Res; 2024 Jun; 13(6):1383-1395. PubMed ID: 38973945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer.
    Tibdewal A; Agarwal J; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kaushal R; Kannan S
    BMJ Open; 2021 Feb; 11(2):e041345. PubMed ID: 33589450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study.
    Zhou F; Qin Y; Liu X; Huang J; Wu B; Zhang Z; Yin Z; Yang J; Zhang S; Jiang K; Yang K
    Ther Adv Med Oncol; 2023; 15():17588359231161411. PubMed ID: 36970112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
    Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
    Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
    Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
    Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation.
    Wen M; Xia J; Sun Y; Wang X; Fu X; Zhang Y; Zhang Z; Zhou Y; Li X
    Biologics; 2018; 12():183-190. PubMed ID: 30555222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
    Huang CY; Wang L; Feng CJ; Yu P; Cai XH; Yao WX; Xu Y; Liu XK; Zhu WJ; Wang Y; Zhou J; Lu Y; Wang YS
    Oncotarget; 2016 Oct; 7(41):66480-66490. PubMed ID: 26624882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.